Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07GHV
|
|||
| Former ID |
DNCL003129
|
|||
| Drug Name |
PF-05180999
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 1 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H17F3N8
|
|||
| Canonical SMILES |
CC1=NC(=C2N1N=CN=C2N3CCC3)C4=C(N(N=C4)C)C5=NC=C(C=C5)C(F)(F)F
|
|||
| InChI |
1S/C19H17F3N8/c1-11-27-15(17-18(29-6-3-7-29)24-10-26-30(11)17)13-9-25-28(2)16(13)14-5-4-12(8-23-14)19(20,21)22/h4-5,8-10H,3,6-7H2,1-2H3
|
|||
| InChIKey |
CLGCHUKGBICQTE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1394033-54-5
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01530529) A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.